Loading…
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $110M | $-136M | $-153M | $-163M | 145.5% | 21.4% | - |
| 2024 | $90M | $-110M | $-127M | $-97M | 1441.3% | 9.3% | - |
| 2023 | $83M | $-82M | $-102M | $-77M | 156.8% | 28.5% | - |
| 2022 | $64M | $-98M | $-110M | $-88M | 122.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 64.36 | 82.71 | 90.40 | 109.79 |
| Cost Of Revenue | 7.65 | 9.36 | 8.88 | 12.45 |
| Gross Profit | 56.70 | 73.35 | 81.52 | 97.34 |
| Operating Expense | 135.74 | 138.89 | 178.30 | 222.20 |
| Operating Income | -79.04 | -65.54 | -96.78 | -124.86 |
| EBITDA | -97.77 | -81.90 | -110.33 | -135.66 |
| EBIT | -99.59 | -83.61 | -111.52 | -138.07 |
| Pretax Income | -108.03 | -98.32 | -124.04 | -153.42 |
| Tax Provision | 1.75 | 3.92 | 2.83 | 0.08 |
| Net Income | -109.78 | -102.24 | -126.87 | -153.49 |
| Net Income Common Stockholders | -109.78 | -102.24 | -126.87 | -153.49 |
| Total Expenses | 143.40 | 148.25 | 187.18 | 234.65 |
| Interest Expense | 8.44 | 14.71 | 12.52 | 15.35 |
| Interest Income | 0.94 | 2.64 | 8.90 | 5.96 |
| Research And Development | 52.91 | 45.61 | 57.15 | 67.11 |
| Selling General And Administration | 82.84 | 93.27 | 121.15 | 155.10 |
| Normalized EBITDA | -97.77 | -81.90 | -110.33 | -135.66 |
| Normalized Income | -109.78 | -102.24 | -126.87 | -153.49 |
| Basic EPS | -4.79 | -3.55 | -2.96 | -3.19 |
| Diluted EPS | -4.79 | -3.55 | -2.96 | -3.19 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | -21.56 | -21.55 | -23.41 | 0 |
| Total Unusual Items Excluding Goodwill | -21.56 | -21.55 | -23.41 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -109.78 | -102.24 | -126.87 | -153.49 |
| Reconciled Depreciation | 1.82 | 1.71 | 1.19 | 2.41 |
| Reconciled Cost Of Revenue | 7.65 | 9.36 | 8.88 | 12.45 |
| Net Interest Income | -29.06 | -33.63 | -27.03 | -27.88 |
| Net Income From Continuing And Discontinued Operation | -109.78 | -102.24 | -126.87 | -153.49 |
| Total Operating Income As Reported | -79.04 | -65.54 | -96.78 | -124.86 |
| Diluted Average Shares | 22.81 | 28.83 | 42.88 | 48.12 |
| Basic Average Shares | 22.81 | 28.83 | 42.88 | 48.12 |
| Diluted NI Availto Com Stockholders | -109.78 | -102.24 | -126.87 | -153.49 |
| Net Income Including Noncontrolling Interests | -109.78 | -102.24 | -126.87 | -153.49 |
| Net Income Continuous Operations | -109.78 | -102.24 | -126.87 | -153.49 |
| Other Income Expense | 0.07 | 0.84 | -0.23 | -0.67 |
| Other Non Operating Income Expenses | 0.07 | 0.84 | -0.23 | -0.67 |
| Gain On Sale Of Security | -21.56 | -21.55 | -23.41 | 0 |
| Net Non Operating Interest Income Expense | -29.06 | -33.63 | -27.03 | -27.88 |
| Total Other Finance Cost | 21.56 | 21.55 | 23.41 | 18.50 |
| Interest Expense Non Operating | 8.44 | 14.71 | 12.52 | 15.35 |
| Interest Income Non Operating | 0.94 | 2.64 | 8.90 | 5.96 |
| Operating Revenue | 64.36 | 82.71 | 90.40 | 109.79 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| UroGen Pharma Ltd.this co. | URGN | $1.1B | - | -10.70 | 145.5% | -9.20 |
| CONMED Corporation | CNMD | $1.2B | 25.12 | 1.14 | 4.6% | 11.20 |
| Kestra Medical Technologies, Ltd. | KMTS | $1.1B | - | 3.95 | -55.4% | -6.60 |
| Jade Biosciences, Inc. | JBIO | $1.1B | - | 3.31 | -38.3% | -6.74 |
| InnovAge Holding Corp. | INNV | $1.1B | 161.40 |
| 4.27 |
| -11.5% |
| 25.32 |
| Zenas BioPharma, Inc. | ZBIO | $1.1B | - | - | -156.0% | -3.15 |
| EyePoint, Inc. | EYPT | $1.1B | - | 32.47 | -75.8% | -4.95 |
| Pacira BioSciences, Inc. | PCRX | $1.1B | 149.91 | 1.52 | 1.0% | 10.73 |
| CareDx, Inc. | CDNA | $1.1B | - | 3.49 | -7.0% | -124.58 |
| Peer Median | - | 149.91 | 3.49 | -24.9% | -4.05 | |